Wedbush Securities is making a big statement on Tesla (NASDAQ:TSLA), naming it to its Best Ideas List even though the stock has had a rough start to the year. According to analyst Dan Ives, Tesla ...

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions ...

Wedbush analysts called Palantir one of their "top names" to own in 2025 despite recent losses. Shares of Palantir have lost one-third of their value in the wake of a report last month that the ...

By Trip Gabriel Geoff Nicholson, whose darkly comic literary novels and eclectic nonfiction were full of characters defined by their obsessions — with cartography, Volkswagen Beetles ...

Investing.com-- Analysts at Wedbush Securities have added Tesla Inc (NASDAQ:TSLA) to their "Best Ideas List", citing expectations for a major innovation cycle ahead. Wedbush maintained an ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing exchange-traded fund market. With more than 7K ETFs listed globally, collectively managing over $10T in ...

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions, introduces ...

As previously reported, Wedbush analyst Alicia Reese upgraded Logitech (LOGI) to Outperform from Neutral with a price target of $125, up from $100, after management clarified during the company ...

Welltower (NYSE:WELL) was upgraded at Wedbush after the senior housing REIT "impressed with the growth outlook for 2025". The healthcare REIT turned in Q4 earnings and revenue that topped Wall ...

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Wednesday,RTT News reports.

Wedbush has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share.